SEC For	m 4																
FORM 4 UNI				NITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549											OMB APPROVAL		
Section 16. Form 4 or Form 5 obligations may continue. See						AT OF CHANGES IN BENEFICIAL OWNE d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940							SHIP OMB Number: 3235-0287 Estimated average burden hours per response: 0.5				
1. Name and Address of Reporting Person* <u>Izumi Raquel E.</u> (Last) (First) (Middle) 260 SHERIDAN AVENUE, SUITE 400					2. Issuer Name and Ticker or Trading Symbol <u>Vincerx Pharma, Inc.</u> [VINC] 3. Date of Earliest Transaction (Month/Day/Year) 05/23/2024							Relationship of Reporting Person(s) to Issuer heck all applicable) X Director 10% Owner X Officer (give title Other (specify below) See Remarks					
(Street) PALO ALTO CA 94306 (City) (State) (Zip)				4.	Line) X Form								Joint/Group Filing (Check Applicable filed by One Reporting Person filed by More than One Reporting n				
	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date					Execution Date		Date	Code (Inst	on Disposed tr. 5)	ed Of (D) (Instr. 3, 4 a		Securitie Beneficia Owned F Reported Transact (Instr. 3 a	s Form lly (D) of ollowing (I) (In on(s)		: Direct r Indirect str. 4)	of Indirect Beneficial Ownership (Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Ye	Code				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (right to buy)	\$7.38	05/23/2024 ⁽¹⁾		А		41,250		(2)	03/06/2034	Common Stock	41,250	\$0.00	165,00	00	D		

Explanation of Responses:

1. The option grant was approved on March 7, 2024, subject to stockholder approval of an amendment to the Vincerx Pharma, Inc. 2020 Stock Incentive Plan. The stockholders approved the amendment on May 23, 2024.

2. One-third (1/3) vests on March 7, 2025, with the remainder vesting in twenty-four equal monthly installments thereafter.

Remarks:

President and Chief Operations Officer

By: /s/ Raquel E. Izumi

** Signature of Reporting Person

05/29/2024 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.